Pazopanib Tablet: A Breakthrough in Targeted Cancer Therapy

1. Composition and Pharmacological Overview Pazopanib Tablet
Pazopanib is a multi-targeted tyrosine kinase inhibitor that falls under the class of oral anti-cancer agents. Each tablet typically contains 200 mg or 400 mg of pazopanib hydrochloride as the active ingredient. In addition to the active compound, the tablets contain excipients like magnesium stearate, microcrystalline cellulose, and hypromellose which facilitate tablet formation and stability.
Pharmacologically, Pazopanib demonstrates high specificity for several growth factor receptors, such as vascular endothelial growth factor receptors (VEGFR)-1, -2, and -3, platelet-derived growth factor receptors (PDGFR)-α and -β, and c-kit. These receptors are known to play a critical role in angiogenesis and tumor proliferation. By targeting these receptors, Pazopanib effectively hampers the growth of new blood vessels that feed tumors, thereby starving the cancer cells.
________________________________________
2. Mechanism of Action: How Pazopanib Works
Pazopanib works by inhibiting angiogenesis—the formation of new blood vessels. Tumors require an extensive network of blood vessels to grow and metastasize. By selectively blocking VEGFR, PDGFR, and c-kit, Pazopanib cuts off the supply line to tumors, thus slowing or halting their progression.
The drug's mechanism also makes it especially suitable for tumors that are heavily reliant on vascular support, such as renal cell carcinomas. Its ability to act on multiple pathways provides a multifaceted attack on cancer, reducing the likelihood of resistance.